How to cite this paper
Eweas, A., Abdallah, Q & Elbadawy, M. (2021). Synthesis and biological evaluation of some new 2-pyridylquinazoline derivatives.Current Chemistry Letters, 10(4), 459-470.
Refrences
1 Hameed A., Al-Rashida M., Uroos M., Ali S. A., Arshia, Ishtiaq M., and Khan K. M. (2018) Quinazoline and quinazolinone as important medicinal scaffolds: A comparative patent review (2011–2016). Expert Opin. Ther. Pat., 28 (4) 281-297.
2 Gupta T., Rohilla A., Pathak A., Akhtar M. J., Haider M. R., and Yar M. S. (2018) Current perspectives on quinazolines with potent biological activities: A review. Synth. Commun, 48 (10) 1099-1127.
3 Rajput C. S., and Singhal S. (2013) Synthesis, characterization, and anti-inflammatory activity of newer quinazolinone analogs. J. Pharm., 2013.
4 Bule M. H., Ahmed I., Maqbool F., and Zia M. A. (2017) Quinazolinone derivatives as a potential class of compounds in malaria drug discovery. Int. J. Pharm., 13(7) 818-831.
5 Liu J.-F., Kaselj M., Isome Y., Ye P., Sargent K., Sprague K., Cherrak D., Wilson C. J., Si Y., and Yohannes D. (2006) Design and synthesis of a quinazolinone natural product-templated library with cytotoxic activity. J. Comb. Chem, 8(1) 7-10.
6 Koepfli J., Brockman Jr J. A., and Moffat J. (1950) The structure of febrifugine and isofebrifugine1. J. Am. Chem. Soc., 72(7) 3323-3323.
7 Cornforth J. W. (1976) Structures of isamic acid and methylisatoid. J. Chem. Soc. Perkin Trans. I, 1 (19) 2004-2009.
8 Honda G., Tosirisuk V., and Tabata M. (1980) Isolation of an antidermatophytic, tryptanthrin, from indigo plants, polygonum tinctorium and isatis tinctoria. Planta Med., 38(3) 275-276.
9 Sheu, J. R. (1999). Pharmacological effects of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Cardiovasc. Drug Rev., 17(3), 237-245.
10 Cambridge D., Davey M., and Massingham R. (1977) Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. Br. J. Pharmacol., 59(3) 514P.
11 Hara H., Ichikawa M., Oku H., Shimazawa M., and Araie M. (2005) Bunazosin, a selective α1‐adrenoceptor antagonist, as an anti‐glaucoma drug: Effects on ocular circulation and retinal neuronal damage. Cardiovasc. Ther., 23(1) 43-56.
12 Jardin A., Bensadoun H., Delauche-Cavallier M., and Attatli P. (1991) Alfuzosin for treatment of benign prostatic hypertrophy. The Lancet, 337(8755) 1457-1461.
13 Da Matta Guedes P. M., Urbina J. A., De Lana M., Afonso L. C., Veloso V. M., Tafuri W. L., Machado-Coelho G. L., Chiari E., and Bahia M. T. (2004) Activity of the new triazole derivative albaconazole against trypanosoma (schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother, 48(11) 4286-4292.
14 Ugale V. G., and Bari S. B. (2014) Quinazolines: New horizons in anticonvulsant therapy. Eur. J. Med. Chem., 80 447-501.
15 Gurram V., Garlapati R., Thulluri C., Madala N., Kasani K. S., Machiraju P. K., Doddapalla R., Addepally U., Gundla R., and Patro B. (2015) Design, synthesis, and biological evaluation of quinazoline derivatives as α-glucosidase inhibitors. Med. Chem. Res., 24(5) 2227-2237.
16 Eweas A. F., El-Nezhawy A. O., Baiuomy A. R., and Awad M. M. (2013) Design, synthesis, anti-inflammatory, analgesic screening, and molecular docking of some novel 2-pyridyl (3h)-quinazolin-4-one derivatives. Med. Chem. Res., 22(2) 1011-1020.
17 Kashaw S. K., Gupta V., Kashaw V., Mishra P., Stables J., and Jain N. (2010) Anticonvulsant and sedative-hypnotic activity of some novel 3-[5-(4-substituted) phenyl-1, 3, 4-oxadiazole-2yl]-2-styrylquinazoline-4 (3h)-ones. Med. Chem. Res., 19(3) 250-261.
18 Abuelizz H. A., Hassane A. E., Marzouk M., Ezzeldin E., Ali A. A., and Al-Salahi R. (2017) Molecular modeling, enzyme activity, anti-inflammatory and antiarthritic activities of newly synthesized quinazoline derivatives. Future Med. Chem., 9 (17) 1995-2009.
19 Alafeefy A. M., Kadi A. A., El‐Azab A. S., Abdel‐Hamide S. G., and Daba M. H. Y. (2008) Synthesis, analgesic and anti‐inflammatory evaluation of some new 3h‐quinazolin‐4‐one derivatives. Arch. Pharm., 341(6) 377-385.
20 Ward A., Dong L., Harris J. M., Khanna K. K., Al-Ejeh F., Fairlie D. P., Wiegmans A. P., and Liu L. (2017) Quinazolinone derivatives as inhibitors of homologous recombinase rad51. Bioorg. Med. Chem. Lett., 27 (14) 3096-3100.
21 Siddique M. U. M., Mccann G. J., Sonawane V. R., Horley N., Gatchie L., Joshi P., Bharate S. B., Jayaprakash V., Sinha B. N., and Chaudhuri B. (2017) Quinazoline derivatives as selective cyp1b1 inhibitors. Eur. J. Med. Chem., 130, 320-327.
22 Modh R. P., De Clercq E., Pannecouque C., and Chikhalia K. H. (2014) Design, synthesis, antimicrobial activity and anti-hiv activity evaluation of novel hybrid quinazoline–triazine derivatives. J Enzyme Inhib Med Chem, 29(1) 100-108.
23 Marzaro G., Guiotto A., and Chilin A. (2012) Quinazoline derivatives as potential anticancer agents: A patent review (2007–2010). Expert Opin Ther Pat., 22(3) 223-252.
24 Ravez S., Castillo-Aguilera O., Depreux P., and Goossens L. (2015) Quinazoline derivatives as anticancer drugs: A patent review (2011–present). Expert Opin Ther Pat., 25(7) 789-804.
25 Tunitskaya, V. L., Khomutov, A. R., Kochetkov, S. N., Kotovskaya, S. K., & Charushin, V. N. (2011). Inhibition of DNA gyrase by levofloxacin and related fluorine-containing heterocyclic compounds. Acta Naturae (англоязычная версия), 3(4 (11)).
26 Kelley C., Zhang Y., Parhi A., Kaul M., Pilch D. S., and Lavoie E. J. (2012) 3-phenyl substituted 6, 7-dimethoxyisoquinoline derivatives as ftsz-targeting antibacterial agents. Bioorganic Med. Chem., 20(24) 7012-7029.
27 Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65(1-2) 55-63.
28 Cockerill F. R., Wikler M., Bush K., Dudley M., Eliopoulos G., and Hardy D. (2012) Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement.
29 Vandepitte J., Verhaegen J., Engbaek K., Rohner P., Piot P., Heuck C., and Heuck C. (2003) Basic laboratory procedures in clinical bacteriology, Ed, World Health Organization.
30 Qaiyumi S. (2007) Macro-and microdilution methods of antimicrobial susceptibility testing, Ed, CRC Press, Boca Raton, London, New York.
2 Gupta T., Rohilla A., Pathak A., Akhtar M. J., Haider M. R., and Yar M. S. (2018) Current perspectives on quinazolines with potent biological activities: A review. Synth. Commun, 48 (10) 1099-1127.
3 Rajput C. S., and Singhal S. (2013) Synthesis, characterization, and anti-inflammatory activity of newer quinazolinone analogs. J. Pharm., 2013.
4 Bule M. H., Ahmed I., Maqbool F., and Zia M. A. (2017) Quinazolinone derivatives as a potential class of compounds in malaria drug discovery. Int. J. Pharm., 13(7) 818-831.
5 Liu J.-F., Kaselj M., Isome Y., Ye P., Sargent K., Sprague K., Cherrak D., Wilson C. J., Si Y., and Yohannes D. (2006) Design and synthesis of a quinazolinone natural product-templated library with cytotoxic activity. J. Comb. Chem, 8(1) 7-10.
6 Koepfli J., Brockman Jr J. A., and Moffat J. (1950) The structure of febrifugine and isofebrifugine1. J. Am. Chem. Soc., 72(7) 3323-3323.
7 Cornforth J. W. (1976) Structures of isamic acid and methylisatoid. J. Chem. Soc. Perkin Trans. I, 1 (19) 2004-2009.
8 Honda G., Tosirisuk V., and Tabata M. (1980) Isolation of an antidermatophytic, tryptanthrin, from indigo plants, polygonum tinctorium and isatis tinctoria. Planta Med., 38(3) 275-276.
9 Sheu, J. R. (1999). Pharmacological effects of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Cardiovasc. Drug Rev., 17(3), 237-245.
10 Cambridge D., Davey M., and Massingham R. (1977) Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. Br. J. Pharmacol., 59(3) 514P.
11 Hara H., Ichikawa M., Oku H., Shimazawa M., and Araie M. (2005) Bunazosin, a selective α1‐adrenoceptor antagonist, as an anti‐glaucoma drug: Effects on ocular circulation and retinal neuronal damage. Cardiovasc. Ther., 23(1) 43-56.
12 Jardin A., Bensadoun H., Delauche-Cavallier M., and Attatli P. (1991) Alfuzosin for treatment of benign prostatic hypertrophy. The Lancet, 337(8755) 1457-1461.
13 Da Matta Guedes P. M., Urbina J. A., De Lana M., Afonso L. C., Veloso V. M., Tafuri W. L., Machado-Coelho G. L., Chiari E., and Bahia M. T. (2004) Activity of the new triazole derivative albaconazole against trypanosoma (schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother, 48(11) 4286-4292.
14 Ugale V. G., and Bari S. B. (2014) Quinazolines: New horizons in anticonvulsant therapy. Eur. J. Med. Chem., 80 447-501.
15 Gurram V., Garlapati R., Thulluri C., Madala N., Kasani K. S., Machiraju P. K., Doddapalla R., Addepally U., Gundla R., and Patro B. (2015) Design, synthesis, and biological evaluation of quinazoline derivatives as α-glucosidase inhibitors. Med. Chem. Res., 24(5) 2227-2237.
16 Eweas A. F., El-Nezhawy A. O., Baiuomy A. R., and Awad M. M. (2013) Design, synthesis, anti-inflammatory, analgesic screening, and molecular docking of some novel 2-pyridyl (3h)-quinazolin-4-one derivatives. Med. Chem. Res., 22(2) 1011-1020.
17 Kashaw S. K., Gupta V., Kashaw V., Mishra P., Stables J., and Jain N. (2010) Anticonvulsant and sedative-hypnotic activity of some novel 3-[5-(4-substituted) phenyl-1, 3, 4-oxadiazole-2yl]-2-styrylquinazoline-4 (3h)-ones. Med. Chem. Res., 19(3) 250-261.
18 Abuelizz H. A., Hassane A. E., Marzouk M., Ezzeldin E., Ali A. A., and Al-Salahi R. (2017) Molecular modeling, enzyme activity, anti-inflammatory and antiarthritic activities of newly synthesized quinazoline derivatives. Future Med. Chem., 9 (17) 1995-2009.
19 Alafeefy A. M., Kadi A. A., El‐Azab A. S., Abdel‐Hamide S. G., and Daba M. H. Y. (2008) Synthesis, analgesic and anti‐inflammatory evaluation of some new 3h‐quinazolin‐4‐one derivatives. Arch. Pharm., 341(6) 377-385.
20 Ward A., Dong L., Harris J. M., Khanna K. K., Al-Ejeh F., Fairlie D. P., Wiegmans A. P., and Liu L. (2017) Quinazolinone derivatives as inhibitors of homologous recombinase rad51. Bioorg. Med. Chem. Lett., 27 (14) 3096-3100.
21 Siddique M. U. M., Mccann G. J., Sonawane V. R., Horley N., Gatchie L., Joshi P., Bharate S. B., Jayaprakash V., Sinha B. N., and Chaudhuri B. (2017) Quinazoline derivatives as selective cyp1b1 inhibitors. Eur. J. Med. Chem., 130, 320-327.
22 Modh R. P., De Clercq E., Pannecouque C., and Chikhalia K. H. (2014) Design, synthesis, antimicrobial activity and anti-hiv activity evaluation of novel hybrid quinazoline–triazine derivatives. J Enzyme Inhib Med Chem, 29(1) 100-108.
23 Marzaro G., Guiotto A., and Chilin A. (2012) Quinazoline derivatives as potential anticancer agents: A patent review (2007–2010). Expert Opin Ther Pat., 22(3) 223-252.
24 Ravez S., Castillo-Aguilera O., Depreux P., and Goossens L. (2015) Quinazoline derivatives as anticancer drugs: A patent review (2011–present). Expert Opin Ther Pat., 25(7) 789-804.
25 Tunitskaya, V. L., Khomutov, A. R., Kochetkov, S. N., Kotovskaya, S. K., & Charushin, V. N. (2011). Inhibition of DNA gyrase by levofloxacin and related fluorine-containing heterocyclic compounds. Acta Naturae (англоязычная версия), 3(4 (11)).
26 Kelley C., Zhang Y., Parhi A., Kaul M., Pilch D. S., and Lavoie E. J. (2012) 3-phenyl substituted 6, 7-dimethoxyisoquinoline derivatives as ftsz-targeting antibacterial agents. Bioorganic Med. Chem., 20(24) 7012-7029.
27 Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65(1-2) 55-63.
28 Cockerill F. R., Wikler M., Bush K., Dudley M., Eliopoulos G., and Hardy D. (2012) Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement.
29 Vandepitte J., Verhaegen J., Engbaek K., Rohner P., Piot P., Heuck C., and Heuck C. (2003) Basic laboratory procedures in clinical bacteriology, Ed, World Health Organization.
30 Qaiyumi S. (2007) Macro-and microdilution methods of antimicrobial susceptibility testing, Ed, CRC Press, Boca Raton, London, New York.